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How T cell receptor (TCR) specificity evolves in vivo
after protein vaccination is central to the develop-
ment of helper T (Th) cell function. Most models of
clonal selection in the Th cell compartment favor
TCR affinity-based thresholds. Here, we demon-
strated that depot-forming vaccine adjuvants did
not require Toll-like receptor (TLR) agonists to induce
clonal dominance in antigen-specific Th cell re-
sponses. However, readily dispersible adjuvants us-
ing TLR-9 and TLR-4 agonists skewed TCR reper-
toire usage by increasing TCR selection thresholds
and enhancing antigen-specific clonal expansion. In
this manner, vaccine adjuvants control the local ac-
cumulation of Th cells expressing TCR with the high-
est peptideMHC class II binding. Clonal composition
was altered by mechanisms that blocked the local
propagation of clonotypes independently of antigen
dose and not as a consequence of interclonal com-
petition. This capacity of adjuvants to modify anti-
gen-specific Th cell clonal composition has funda-
mental implications for the design of future protein
subunit vaccines.
INTRODUCTION
Vaccines prime the adaptive immune system to anticipate future
pathogens. Most vaccines in use today rely heavily on antigen-
specific B cell memory and the sustained production of high-af-
finity antibodies for effective long-term protection (Kaufmann,
2007; Pulendran and Ahmed, 2006). This high-affinity antigen-
specific B cell memory is dependent on the cognate regulation
of antigen-specific effector Th cells that emerge rapidly upon ini-
tial vaccine challenge (McHeyzer-Williams and McHeyzer-Wil-
liams, 2005). Themechanisms that control clonal selection within
the antigen-specific Th cell compartment are central to the de-
velopment of appropriate effector Th cells, but the details of
these processes remain poorly resolved.
Initial T cell receptor (TCR) recognition of foreign peptide MHC
class II (pMHCII) complexes on antigen-presenting cells (APCs)
defines the first major checkpoint in antigen-specific Th cell de-
velopment (Fazilleau et al., 2007b; McHeyzer-Williams and
McHeyzer-Williams, 2005). Unlike CD8+ T cells, Th cells require698 Immunity 28, 698–709, May 2008 ª2008 Elsevier Inc.persistent TCR-pMHCII interactions for maximal clonal expan-
sion (Obst et al., 2005) that may arise from multiple contacts
with pMHCII-expressing APCs (Celli et al., 2005). Individual
TCR-pMHCII interactions are characteristically low affinity in-
volving conformational co-operativity (Rudolph et al., 2006)
with TCR junctional region plasticity upon binding (Reiser et al.,
2002) and multimer formation at the Th-APC cellular interface
(Davis et al., 2007). Nevertheless, most models still favor TCR
affinity thresholds or functional avidity for pMHC binding as
controlling ‘‘best fit’’ for antigen-specific TCR selection and
evidence for peptide-binding kinetics determining clonal domi-
nance (Lazarski et al., 2005). Specifically in the peripheral Th
cell compartment, there is evidence for preservation of clono-
types with slower TCR offrates (Savage et al., 1999), indications
of competition for antigen among monoclonal Th cells (Falta
et al., 2005; Fasso et al., 2000; Garcia et al., 2007; Rees et al.,
1999), and overall TCR affinity-based selection (Malherbe et al.,
2000;Malherbeetal., 2004;Skokosetal., 2007;Weberetal., 2005).
Importantly, thedurationofTh-APCcontact (Iezzi etal., 1998;Miller
et al., 2004) and the strength of TCR-pMHCII binding (Gett et al.,
2003; Lee et al., 2003) can impact clonal expansion (Celli et al.,
2007) and the differential acquisition of effector Th cell function
(Chang et al., 2007; Lanzavecchia and Sallusto, 2002; Reiner
et al., 2007). Hence, the dynamics of clonal evolution among
antigen-specific Th cells can fundamentally impact all subse-
quent phases of Th-cell-regulated adaptive immunity.
The I-Ek restricted murine response to pigeon cytochrome
c (PCC) (Jorgensen et al., 1992) provides access to antigen-
specific Th cells as they develop in vivo (Bikah et al., 2000;
McHeyzer-Williams et al., 1999; McHeyzer-Williams and Davis,
1995; Panus et al., 2000). Local vaccination with whole protein
into B10.BR mice induces Va11Vb3-expressing Th cells with
a limited set of TCR junctional regions that confer specificity to
one dominant PCC epitope (McHeyzer-Williams et al., 1999). Ap-
pearance of these PCC-specific TCRs helps to define the dy-
namics of clonal evolution and the extent of clonal diversity
within the antigen-specific Th cell response (Malherbe et al.,
2004; McHeyzer-Williams and McHeyzer-Williams, 2004;
McHeyzer-Williams et al., 1999). In this model of protein vaccina-
tion, clonal selection occurs rapidly over a threshold TCR affinity
for pMHCII without further bias toward higher-affinity TCR above
this threshold (Malherbe et al., 2004). Surprisingly, lowering anti-
gen dose until clonal expansion was compromised has no effect
on clonal diversity. Overall, the selection mechanism for Th
cells appears to be ‘‘programmed’’ early during the immune re-
sponse, ‘‘intrinsic’’ to the affinity of the expressed TCR, and
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Adjuvants Regulate TCR selectionFigure 1. Local Accumulation of Antigen-
Specific Th Cells across Different Adjuvants
(A and B) PCC-specific Th cells (Va11+Vb3+CD44hi
CD62Llo) at day 7 in lymph nodes from B10.BR
mice immunized with (A) Alum with (lower panels)
or without PCC (upper panels) or (B) with PCC
and the indicated adjuvant. Profiles gated on
propidium iodide (PI)-negative cells that are
CD4+B220CD8CD11b and Va11+Vb3+ are
shown as indicated with mean ± SEM (nR 3) per-
centage of cells within insert box.
(C) Total number of PCC-specific Th cells 7 days
after immunization with Alum (n = 7), IFA (n = 6),
CFA (n = 15), CpG (n = 6), and MPL (n = 25) with
(bars) or without PCC (circles); means ± SEM;
n R 3; p % 0.01 (**) (two-tailed t test) comparing
Alum or MPL to any other adjuvant.
(D) Total number of PCC-specific Th cells 3, 5, 7,
or 9 days after immunization with IFA and PCC.
Mean ± SEM for at least three animals.not dependent on clonal competition (Fazilleau et al., 2007b).
Whether this clonal selection mechanism can be regulated by
secondary microenvironmental cues that alter Th cell clonal
composition remains unknown.
All vaccines deliver antigens within an inflammatory context to
prime antigen-specific immune responses (Medzhitov and Jane-
way, 1997). In particular, protein subunit vaccine formulations all
require an exogenous vaccine adjuvant to provide this inflamma-
tory context and promote effective immunity (Guy, 2007; Pashine
et al., 2005; Pulendran and Ahmed, 2006). Aluminum-containing
adjuvants (Alum) and Incomplete Freund’s adjuvant (IFA) contain
no known TLR-agonist activity but promote depots of antigen at
the injection site and support protective immunity in humans and
mice (Lindblad, 2004). In contrast, Complete Freund’s adjuvant
(CFA) includes a complex mixture of inflammatory mediators
through the addition of heat-killed mycobacterium into the min-
eral oil of IFA (Billiau and Matthys, 2001; Garcon et al., 2007).
Aqueous formulations of CpG oligodeoxynucleotide and antigen
are TLR-9-agonist-driven adjuvants with no capacity to promote
antigen depots (Klinman, 2006). Similarly, an oil-in-water mono-
phosphoryl lipid A (MPL)-based adjuvant provides a TLR-4-
driven immune stimulant (Baldridge et al., 2004; Garcon et al.,
2007) with antigen in metabolizable squalene oil (O’Hagan,
2007). These adjuvants are used across many protein vaccina-
tion models; however, their impact on clonal selection within
the helper T cell compartment is not known.
In the current studies, varying vaccine adjuvants revealed the
dynamics of a unique mechanism of antigen-specific Th cell se-
lection. Although all adjuvants induced clonal dominance in the
helper T cell compartment, the antigen-specific TCR repertoire
was differentially skewed across the different formulations. Inde-
pendent of TLR activity, all depot adjuvants (Alum, IFA, and CFA)
promoted antigen-specific clonotypes expressing different sets
of TCR with lower pMHCII binding. In contrast, the dispersibleadjuvants (CpG andMPL) reset the TCR-based selection thresh-
old to recruit and propagate clonotypes with higher pMHCII
binding. In this manner and independently of antigen dose, vac-
cine adjuvants control the local penetrance of Th cells express-
ing TCR with the highest peptide MHC class II binding. Thus, al-
tering TCR-based selection thresholds with different vaccine
adjuvant formulations provides a fundamentally newmechanism
for regulating adaptive immunity.
RESULTS
Local Accumulation of Antigen-Specific Th Cells across
Different Adjuvants
An MPL-based oil-in-water adjuvant induces maximal clonal ac-
cumulation in draining lymph nodes (LNs) of B10.BR mice at day
7 after subcutaneous priming with 400 mg whole protein antigen
PCC (McHeyzer-Williams et al., 1999). Here, we compared
the LN accumulation of PCC-specific Th cells (Va11+Vb3+
CD44hiCD62Llo) across five different vaccine adjuvants com-
monly used in murine immune response models (Figures 1A
and 1B). Precipitating protein antigen with Alum induced the low-
est number of PCC-specific Th cells (Figures 1A and 1C). In con-
trast, IFA induced significantly higher numbers of PCC-specific
Th cells (Figures 1B and 1C) with a peak reached at day 7 (Fig-
ure 1D). CFA without antigen induces higher levels of back-
ground than Alum or IFA alone (Figure 1C, white circles) but sur-
prisingly induces similar levels of PCC-specific Th cells as IFA
(Figures 1B and 1C). Dispersible aqueous formulations of the
TLR-9 agonist CpG and PCC also induced similar amounts of
clonal accumulation as the IFA and 50% fewer cells than
CFA. Finally, the MPL-based adjuvant induced significantly
higher local accumulation of PCC-specific Th cells (p < 0.001)
compared to all other adjuvants. These data reveal a hierarchy
of antigen-specific Th cell responsiveness that appears to beImmunity 28, 698–709, May 2008 ª2008 Elsevier Inc. 699
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Adjuvants Regulate TCR selectionFigure 2. Clonal Dominance without TLR Agonists or Antigen Depots
Single-cell repertoire analysis of individual PCC-specific Th cells (Va11+Vb3+CD44hiCD62Llo) sorted from mice immunized with PCC and indicated adjuvant.
(A) Each filled circle represents sequence from single cells representing the number of preferred CDR3 features known to be selected in the PCC response (TCR-
a: E at a93; S at a 95; CDR3a length of 8aa; and TCRJ a 16, 17, 22, and 34. TCR-b: N at b100; A, G at b102; CDR3b length of 9aa; and TCRJ b 1.2 and 2.5). Cells
with greater than or equal to six preferred features express restricted TCR of the dominant clonotype and the percentage ± SEM; across three individual animals
with n = number of single cells used in the analysis displayed with individual animals contributing different numbers of sequences, Alum (n = 21, 23, and 16); IFA
(n = 22, 18, and 18); CFA (n = 18, 17, and 18); CpG (n = 15, 16, and 17) MPL (n = 16, 19, and 17).
(B) TCR sequences from the dominant clonotypes (greater than or equal to six preferred CDR3 features). Columns (left to right) show the following: individual
CDR3a chain designation (based on amino acids at a93 and a95, CDR3a length, and J a usage); CDR3a, with positions a93E and a95S ‘‘highlighted’’ in black
as canonical, motif length depicted; J a gene usage; individual CDR3b designation (based on amino acids at b100 and b102, CDR3b length and J b usage);
CDR3b, with positions b100N and b102A or b102G ‘‘highlighted’’ in black as canonical, motif length depicted; Jb gene segment usage; total number of
‘‘preferred’’ features in both CDR3 regions combined.700 Immunity 28, 698–709, May 2008 ª2008 Elsevier Inc.
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tion across the five different adjuvant formulations.
Although there was an increase of CD44hiCD62Lhi Va11+Vb3+
cells at day 7 of the primary response across all adjuvants
(Figure S1A available online), their total number (Figure S1B) par-
alleled what was found in the CD44hiCD62Llo compartment. Fur-
thermore, the dynamics of the PCC-specific T cell response was
similar for IFA, CFA, CpG, and MPL with all reaching peak num-
bers at day 7, whereas the Alum response increased to day 9 but
still reached numbers markedly lower than seen for all other ad-
juvant formulations (Figure S2). Thus, the hierarchy of respon-
siveness at day 7 mostly corresponds with the dynamics of the
PCC-specific response.
Clonal Dominance without TLR Agonists
or Antigen Depots
To assess the clonal composition of the PCC-specific Th cell
compartment that accumulates by using the different adjuvants,
we sorted single antigen-specific Thcells for TCR repertoire anal-
ysis. On the basis of early hybridoma analyses (Jorgensen et al.,
1992) and single-cell studies using the MPL-based adjuvant
(Fazilleau et al., 2007a;Malherbe et al., 2004;McHeyzer-Williams
et al., 1999; McHeyzer-Williams and Davis, 1995), we have previ-
ously defined eight preferred features that are within the CDR3 of
the expressed TCRab in B10.BR mice and that assort with PCC-
specificity (CDR3a: Ea93,Sa95, Ja16,22,34,17and lengthof 8aa;
CDR3b: Nb100, A,Gb102, Jb1.2,2.5 and length of 9aa). Single
cells that express TCR with greater than or equal to six of these
preferred features across both chains of the expressed TCR
from individual PCC-specific Th cells define clonal dominance
in this polyclonal immune response (Malherbe et al., 2004;
McHeyzer-Williams et al., 1999; McHeyzer-Williams and Davis,
1995). With this initial level of resolution to the repertoire studies,
it was clear that all five adjuvants induced high levels of clonal
dominance (>70% of responders for all conditions), regardless
of the extent of clonal accumulation (Figure 2A). Thus, TLR ago-
nists or antigen depots are not required to induce clonal domi-
nance in the antigen-specific Th cell compartment.
Vaccine Adjuvants Skew Antigen-Specific TCR
Repertoire Usage
We have previously shown that antigen-specific TCRb trans-
genic Th cells expressing different Jb regions confer broadly dis-
tinct pMHCII-binding properties regardless of the paired TCRa
chain (Malherbe et al., 2004). In particular, PCC-specific TCRb
cells expressing Jb2.5 (2B4b chain) display slower offrates but
overall lower affinity for pMHCII binding than Jb1.2 (5CC7b
chain) (Malherbe et al., 2004). Further, different TCRa chains
pairing with the same TCRb also confer different binding kinetics
that broadly assort with Ja region expression. Thus, it is impor-
tant and informative to scrutinize the clonotypic distribution
within the dominant compartment of PCC-specific responders.
Next, for more in-depth clonal analysis, we broadly divided the
responding set of dominant clones (greater than or equal to six
features) across all adjuvants according to Jb usage and further
designated individual dominant TCRab clonotypes on the basisof preferred CDR3 features (Figures 2B and 2C). Clonotypes ex-
pressing Jb2.5 were more prevalent when using the three depot-
forming adjuvants (Alum: 45%, IFA: 42% and CFA: 41%) (top
panel in each section) than the nondepot-forming adjuvant
(CpG: 25% and MPL: 14%). The Jb2.5-expressing clonotypes
displayed restricted TCRa chains (on the basis of preferred fea-
tures), but many used noncanonical Ja segments expressed
(Figure 2C, top panel). Interestingly, among the depot adjuvants
(Alum, IFA, and CFA), Jb2.5-expressing clonotypes were pre-
dominantly nonoverlapping (Figure 2B, top panel). In contrast,
clonotypes expressing Jb1.2 displayed highly restricted TCRa
chains with predominantly canonical Ja regions (Figure 2C, bot-
tom panel) and emerged to dominant levels when using the two
nondepot adjuvant formulations (CpG: 54% and MPL: 56%)
(Figure 2B, bottom panel). These data indicate that different
adjuvants promote the local accumulation of antigen-specific
Th cells with broadly differing TCR repertoires.
Skewed J Region Usage among Dominant Clonotypes
Because of the substantial clonal heterogeneity in nontransgenic
animals, it is reasonable to consider the variation of individual
CDR3 features as a means of evaluating the impact of adjuvant
on clonal variation (Figures S3 and S4). These analyses again
highlight TCRa chain variation predominantly based on Ja region
usage (Figure S3A). Across the depot adjuvants, IFA promoted
the highest frequency of the dominant clonotypes (71% ± 3%)
with many expressing Ja22 (44%). Alum and CFA promoted
a lower proportion of the dominant clonotypes (55 ± 15% and
49 ± 6% respectively) with far fewer Ja22 clonotypes (11%
and 12%) but many clones expressing Ja16 (32% and 23%)
and Ja17 (32% and 54%). Both nondepot adjuvants favored
dominant clonotypes expressing Ja22 (CpG: 46% and MPL:
43%). All other CDR3a features were highly restricted across
all adjuvant formulations (Figures 3B–3D). As suggested by the
clonal analysis, the Jb region usage was the most consistent
and systematic change encountered (Figure S4A) and will be
pursued in greater detail throughout these studies. The CDR3b
feature of G or A at b102 also assorts with the Jb region differ-
ences (Figure S4B) contributed by the Db2 or Db1 segment, re-
spectively. The CDR3b length of 9aa (Figure S4C) and the selec-
tion for N at b100 (Figure S4D) were similarly restricted across all
adjuvants. These data further support the capacity of vaccine
adjuvants to skew J region gene usage among the TCR reper-
toire of the dominant antigen-specific Th cell compartment.
Vaccine Adjuvants Impact Local Clonal Composition
Next, we extended clonal analysis across the different adjuvants
focused on Jb region usage including an alternate RT-PCR-
based assaywith single-cell resolution for Jb1.2 and Jb2.5 usage
(see Experimental Procedures for details). As indicated from the
previous clonal analysis, CpG- and MPL-based adjuvant mark-
edly skewed the responding Th cell compartment toward clones
expressing Jb1.2 (Figure 3A). To monitor the impact of adjuvant
on CDR3b chain, we considered the distribution of five dominant
TCRb chains regardless of TCRa chain assortment (Figure 3B).
Jb2.5-expressing clones similar to the TCRb from PCC-specific(C) Penetrance of dominant clonotypes after priming with PCC and the indicated adjuvant as a percentage of dominant clonotypes and organized in the same
order as (B) with summaries for each adjuvant across Jb2.5 and Jb1.2 usage as displayed.Immunity 28, 698–709, May 2008 ª2008 Elsevier Inc. 701
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and IFA but were only found in low frequencies from animals
immunized with CFA. In contrast, CFA promoted two different
CDR3b chains, one similar to the hybridoma 2C2b and the other
designated NWG-1.2b. As predicted, Jb1.2 usage was present
with the depot adjuvants at variable penetrance for some clono-
types as evidenced by NSA-1.2b but increasing frequencies
were found after CpG- and MPL-based adjuvant as exemplified
by the penetrance of TCR with 5CC7 b chain (Figure 3B). Finally,
clonal expansion also played a role in the propagation of partic-
ular selected clonotypes as demonstrated by the substantial ex-
aggeration of the 5CC7b chain expressing clonotype after MPL
adjuvant that was not evident with CpG (Figure 3C). Thus, adju-
vant formulation can substantially alter clonal composition and
the MPL-based adjuvant can preferentially promote antigen-
specific Th cells with broadly higher pMHCII binding.
Adjuvants Reset TCR Selection Thresholds
Labeling with pMHCII tetramers provides a direct means to visu-
alize TCR ligand binding by antigen-specific Th cells. The mean
Figure 3. Adjuvants Skew TCRb Chain Usage
(A) Relative abundance of PCC-specific Th cells (Va11+Vb3+CD44hiCD62Llo)
expressing Jb1.2 or Jb2.5 gene segments for the indicated adjuvant (mean ±
SEM; nR 3).
(B) Predicted amino acid sequences of CDR3b regions mean ± SEM of five
predominant clonotypes (n R 3) for PCC-specific Th cells isolated from
mice immunized with indicated adjuvant.
(C) Total number of PCC-specific Th cells expressing the 5C.C7b
(SLNNANSDY) rearrangement mean ± SEM nR 3.702 Immunity 28, 698–709, May 2008 ª2008 Elsevier Inc.fluorescence intensity (MFI) for pMHCII binding at optimal con-
centrations of pMHCII tetramer provides an index for the amount
and distribution of TCR binding strength within polyclonal anti-
gen-specific Th cell compartments. Importantly, in the current la-
beling strategy (Figures 4A and 4B), Va11 MFI also estimated to-
tal TCR expression per cellular population and were similar
across all adjuvant conditions. The pMHCII-based assay for
monitoring Th cell responses had a lower background for all ad-
juvant-only controls (Figure 4C, white circles) but detected
50% fewer pMHCII+Va11+ antigen-specific Th cells than with
the V region-based strategy (that doesn’t require pMHCII binding
in Figure 1). Nevertheless, similar relative differences of clonal
accumulation across different adjuvants (Figures 4A–4C) parallel
that found with the TCR V region-based assay (in Figure 1A).
Even though the cellular response was low, Alum induced
a broad range of pMHCII tetramer binding (Figures 4A and 4C),
but the population expressed the lowest pMHCII MFI compared
to all other adjuvants (Figure 4D). A similar range of pMHCII bind-
ing was seen within IFA and CFA responses (Figures 4B and 4C)
but resulted in higher mean fluorescence intensity due to in-
creased presence of high pMHCII-binding cells (Figures 4B
and 4D). The shift toward higher pMHCII-binding cells was more
pronounced with CpG and significantly higher with the MPL-
based adjuvant (p < 0.01) (Figures 4B and 4D). These trends in
MFI were consistent with the TCR repertoire studies and suggest
that the MPL-based adjuvant substantially alters clonal compo-
sition by increasing the proportions of high pMHCII-binding Th
cells within the antigen-specific population in the LN.
To test more directly whether polyclonal Th cells that ex-
pressed Jb1.2 bound higher level of pMHCII, we sorted single
antigen-specific Th cells with high versus low levels of pMHCII
binding (Figure S5A). As predicted, TCR with Jb1.2 were pres-
ent to high levels within the pMHCII high binders using CFA or
MPL-based adjuvants. More importantly, Jb2.5-expressing clo-
notypes were only found within the low pMHCII-binding com-
partment (Figure S5B). As a consequence of these studies,
we noted that the proportion of Jb2.5-expressing pMHCII+ Th
cells was lower for the CFA condition than would have been
predicted by the repertoire studies. To evaluate this more
closely, we sorted antigen-specific Th cells after CFA immuni-
zation by using both labeling strategies from individual animals
to evaluate TCR representation (Figure S5C). These data indi-
cated that the pMHCII labeling underestimated the presence
of most Jb2.5-expressing clonotypes because they most prob-
ably fall below the level of detection for this particular reagent.
Appearance of these TCR in vivo revealed by the V region-
based strategy (Figure 2) and a table of PCC-specific hybrid-
omas (Figure S6) suggested that lack of binding reveals the de-
tection limit of the pMHCII reagent and not the specificity of the
Th cells. Nevertheless, the trends of pMHCII binding support
the overall notion that polyclonal antigen-specific TCRs that ex-
press Jb2.5 have a lower capacity for pMHCII binding and that
adjuvants can reset the threshold for clonal selection within the
Th cell compartment.
Blocking the Selection of Low-Affinity Clonotypes
As demonstrated in these analyses, clonal diversity in nontrans-
genic immune responses is substantial. Furthermore, antigen-
specific clonal expansion and effector cell differentiation may
Immunity
Adjuvants Regulate TCR selectionFigure 4. Adjuvants Reset the TCR Selec-
tion Threshold
PCC-specific Th cells as PICD8B220CD11b
cells expressing CD4 and Va11, binding pMHCII
tetramers, and high expression of CD44 displayed
within the inserted box; percentage of cells
mean ± SEM; n R 3 at day 7 in lymph nodes
from B10.BR mice immunized with (A) Alum with
(lower panels) or without PCC (upper panels) or
(B) with PCC and the indicated adjuvant. (C) shows
total numbers of CD4+Va11+pMHCII+CD44hi
CD62Llo Th cells after immunization with (bars) or
without (circles) PCC and the indicated adjuvant;
means ± SEM; n R 3; p % 0.01 (**) (two-tailed
t test) comparing Alum or MPL to any other adju-
vant. (D) shows the mean fluorescence intensity
of pMHCII tetramer staining for PCC-specific
Th cells after immunization with PCC and the
indicated adjuvant (mean ± SEM; nR 3).itself skew the evaluation of TCR binding strength with pMHCII
tetramers andmakes direct comparisons between developmen-
tally distinct Th cell types equivocal. To overcome these issues,
we mixed equal numbers of higher-affinity oligoclonal 5CC7b
(NA9-Jb1.2: SLNNANSDY) and lower-affinity 2B4b (NS9Jb2.5:
NWSQDTQ) TCRb transgenic Th cells and cotransferred them
into B10.BR recipients (Figure 5A). After PCC immunization
with IFA and extensive clonal expansion of transferred cells,
the balance of antigen-specific responder cells from these two
TCRb transgenic sources remained equivalent (Figure 5B). In
contrast, PCC in MPL substantially skewed the responder pop-
ulation toward the higher-affinity 5CC7b clonotype (Figure 5B).
As demonstrated in detail in our previous studies (Malherbe
et al., 2004), the TCR repertoire skewing in the presence of the
MPL-based adjuvant was due to a proportionate loss of the
lower-affinity 2B4b clonotypes and not exaggerated overexpan-
sion of the higher-affinity subtypes. Taken together, these data
indicate that adjuvants regulate clonal composition by using
a mechanism that alters initial TCR-based selection thresholds
and that relies most heavily on blocking the propagation of anti-
gen-specific clonotypes expressing low-affinity TCR.
TCR-Independent Enhancement ofClonal Accumulation
Although different adjuvant formulations are expected to create
depots at the injection site, it is more difficult to ascertain the ef-
fective level of antigen presentation in the draining lymphoid tis-
sue. In a preliminary series of studies, we transferred naive
(Va11+Vb3+CD4+CD44loCD62Lhi) 5CC7ab transgenic Th cells
into B10BR recipients that had been immunized with PCC in
either IFA or the MPL-based adjuvant, day 0, 3, and 5 days after
immunization.We then revealed clonal expansion byusing a con-
genic marker (CD90.2), pMHCII tetramer binding, and CFSE di-
lution 3 days after the transfer. There was evidence for activatingantigen in the draining LNs at each of the three time points tested
with theMPL inducing higher expansion in each case (Figure 6A).
Hence, the MPL-based adjuvant provided as consistent a local
antigen stimulant as the depot forming IFA for at least 5 days
in draining LNs. Importantly, differences in clonal accumulation
were significantly different between IFA and MPL over 7 days
in vivo (p < 0.001) even for Th cells expressing the same mono-
clonal TCRab (Figure 6B). Hence, we suspect that the exagger-
ated clonal accumulation seen with the MPL-based adjuvant in
the polyclonal model is independent of the TCR-based selection
threshold and exerts itself independently of the initial TCR-
pMHCII-binding strength. Nevertheless, TCR-independent influ-
ences of adjuvant can further exaggerate differences in clonal
composition established at the early selection checkpoints in
Th cell recruitment.
Adjuvant Action on Selection Is Independent of Antigen
Dose
In the TCRb transgenic transfer model, we had previously dem-
onstrated that TCR-based selection was independent of antigen
dose (Malherbe et al., 2004). Because of the concern of exagger-
ated precursor frequencies, it was important to readdress this
issue in the context of the polyclonal B10.BR mice (Figure 7A).
With theMPL-based adjuvant, 400 mg and 40 mg of whole protein
antigen induced similar amounts of local Th cell accumulation at
the peak of the PCC-specific response in B10.BR mice
(Figure 7B). In contrast, local antigen-specific Th cell numbers
were significantly truncated with 4 mg of protein antigen. How-
ever, there was no significant increase in the Jb1.2/Jb2.5 ratio
(Figure 7C) or the penetrance of five different sets of TCRb clono-
types as seen with the optimal priming dose of antigen
(Figure 7D). Thus, in the polyclonal model, the MPL-based adju-
vant differentially regulates clonal composition in ways thatImmunity 28, 698–709, May 2008 ª2008 Elsevier Inc. 703
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Affinity Clonotypes
A total of 0.33 3 105 5C.C7b and 1.2 3 105 2B4b
splenocytes were mixed and (A) stained with
pMHCII tetramers for preimmune repertoire analy-
sis or (B) transferred into Thy1.1 syngeneic hosts.
Transferred mice were immunized with 400 mg
PCC in IFA orMPL-based adjuvant. (A) shows rep-
resentative probability contours of pMHCII tetra-
mer staining versus Va11 for 5C.C7b (left) and
2B4b (middle), the 5C.C7b/2B4b cell mixture as
a profile of cells (right) and evaluation of cell origin
after cell sorting (Va11+pMHCII+), and RT-PCR for
Jb1.2/Jb2.5 expression representing 5CC7b and
2B4b, respectively (bar graph). (B) shows repre-
sentative probability contours of CD44 and
CD90.2 expressions (right panel) by Va11+ Vb3+
(left panel) cells from draining lymph nodes of re-
cipient mice 7 days after immunization with IFA
(upper panels) or MPL-based adjuvant (lower
panels); single antigen-experienced PCC-specific
Th cells (Va11+Vb3+CD90.2+CD44hi) were sorted,
and the relative abundance of 5C.C7b and 2B4b
Th cells was evaluated by single-cell RT-PCR
with Jb1.2 and Jb2.5 specific primers, respec-
tively. Means ± SEM; n = 3 for each condition.appear to be independent of clonal expansion and the initial
priming dose of antigen.
DISCUSSION
Overall, these studies using classic vaccine adjuvants revealed
the dynamics of clonal-selection mechanisms in the Th cell com-
partment. Alum supported negligible local clonal accumulation
compared to all other adjuvants, but still promoted clonal dom-
inance. Hence, TLR-agonist activity was not required to promote
clonal dominance with either Alum or IFA. Surprisingly, CFA pro-
moted no further local increase in antigen-specific Th cells than
IFA alone, but did alter clonal composition within selected clono-
types. The antigen depot characteristic of these classical adju-
vants was also not required to induce clonal dominance by the
dispersible TLR-9- and TLR-4-based adjuvants. Most impor-
tantly, the different adjuvants promoted the accumulation of
dominant clonotypes with different TCR repertoires. Alum, IFA,
and CFA promoted antigen-specific Th cells expressing the
Jb2.5 gene segment and lower pMHCII binding. In contrast,
the lower-binding TCR were decreased with CpG and MPL,
thereby substantially altering the local presence of Th cells ex-
pressing Jb1.2 and high pMHCII-binding Th cells. Thus, adjuvant
formulation can modify the TCR-based selection threshold that
regulates Th cell clonal composition in response to protein vac-
cination.
Clonal selection in the Th cell compartment is not altered by
antigen dose. This was a surprising result in our previous studies
using a TCRb chain adoptive transfer model (Malherbe et al.,
2004) and is reproduced here within the polyclonal immune sys-704 Immunity 28, 698–709, May 2008 ª2008 Elsevier Inc.tem. Hence, antigen-specific Th cell clonal selection is not driven
by interclonal competition for antigen. Rather, an intrinsic attri-
bute of the TCR-pMHCII-binding event governs Th cell fate.
Although slower TCR offrates may be selected during thymic
development (Savage et al., 1999) and the memory Th cell
response (Savage et al., 1999), it is the overall pMHCII-binding
capacity of the TCR that is selected at these early checkpoints
in antigen-specific Th cell development. There are reports of
clonal competition for antigen (Falta et al., 2005; Fasso et al.,
2000; Garcia et al., 2007; Rees et al., 1999); such competition
may be a consequence of the adoptive-transfer model and may
not be found in oligoclonal or polyclonal systems. (Malherbe
et al., 2004; McHeyzer-Williams et al., 1999; McHeyzer-Williams
and Davis, 1995). Thus, with limiting numbers of antigen-specific
precursors, the strength of pMHCII binding is the dominant TCR
attribute used to shape theantigen-specific Thcell compartment.
We have proposed that the overall affinity of the TCR-pMHCII
interaction sets the threshold for Th cell clonal selection (Mal-
herbe et al., 2004). With theMPL-based adjuvant and oligoclonal
transfers, the lowest-affinity PCC-specific clonotypes bind
pMHCII but were never recruited into the immune response.
The next-lowest-affinity clonotypes emerged to day 3 of the re-
sponse, but only above a higher-affinity threshold were clono-
types fully propagated to the peak of the local response at day
7. In the polyclonal system (McHeyzer-Williams et al., 1999),
the most diverse antigen-specific clonotypes were also lost be-
tween days 3 and 5 after priming and were not present at the
peak of the response. In this context, we propose that different
adjuvant formulations influence antigen-specific clonal compo-
sition by altering initial TCR-based selection thresholds.
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Adjuvants Regulate TCR selectionFigure 6. TCR-Independent Enhancement of Clonal Accumulation
(A) A total of 23 105 CFSE-labeled 5C.C7ab splenocytes were transferred into syngeneic B10.BR hosts at the time of immunization (upper panels), 3 days (middle
panels) or 5 days (lower panels) after immunization with PCC and IFA or MPL-based adjuvant. Representative probability contours of pMHCII tetramer staining
versus CFSE for IFA (left) and MPL (middle) immunized recipients. Total number of Va11+CFSElopMHCIITet+ cells in draining lymph nodes of recipients immu-
nized with IFA or MPL-based adjuvant in bar graphs (far right).
(B) 2x105 5C.C7ab splenocytes were transferred into CD90.1+ syngeneic hosts and recipients were immunized with PCC and IFA or MPL-based adjuvant. Rep-
resentative probability contours of pMHCII tetramer staining versus CD90.2 for IFA (left) and MPL (middle) immunized recipients. Total number of
Va11+CD90.2+pMHCII+ cells in draining lymph nodes of recipients immunized with IFA or MPL-based adjuvant (far right), mean ± SEM; n = 3; p < 0.01 (**)
(two-tailed Student’s t test).The oligoclonal cotransfer experiments also support an affin-
ity-threshold mechanism that promotes the full propagation of
higher-affinity Th cell responses. It is also possible that different
adjuvants promote differing functional outcomes sequestering
particular clonotypes into separate microenvironmental
niches in vivo (Reinhardt et al., 2001). Clonal analysis of the
CD44hiCD62Lhi PCC-responsive compartment may begin to ex-
amine these issues. Further, the differential export or migration
patterns of Th cell subsets may also alter local clonal composi-
tion and be under the control of differing adjuvants. Studies of
developing Th cell responses under the lymphocyte sequester-
ing action of drugs such as FTY-720 (Mandala et al., 2002)
may help to resolve these issues.The initial stable contact between pMHCII-expressing APC
and naive Th cells may be the defining event in this clonal selec-
tion mechanism. It is plausible that the strength of first contact
indelibly impacts the initial Th cell developmental program
(Chang et al., 2007; Reiner et al., 2007). The program may then
take days to express in vivo, resulting in differential clonal
expansion and effector function (Celli et al., 2007; Gett et al.,
2003; Lanzavecchia and Sallusto, 2002; Lee et al., 2003). In
contrast, multiple TCR-pMHCII contacts are required for maxi-
mal Th cell propagation (Obst et al., 2005) and can occur be-
tweenmultiple dendritic cells (DCs) (Celli et al., 2005) or between
effector Th cells and pMHCII-expressing B cells (Okada et al.,
2005). The rapid selection dynamics in the current modelImmunity 28, 698–709, May 2008 ª2008 Elsevier Inc. 705
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points in Th cell development but does not exclude secondary
influences on cell fate or development because of secondary
TCR-pMHCII interactions (Celli et al., 2005). Our recent studies
correlating strength of TCR-pMHCII binding and the acquisition
of follicular B helper T cell (TFH) function (Fazilleau et al., 2007a)
also implicated early clonal selection mechanisms in the imprint-
ing of subsequent Th cell function. Thus, altering TCR-based se-
lection threshold provides a fundamentally new mechanism to
control Th cell fate and regulate multiple facets of adaptive im-
munity in vivo.
How vaccine adjuvants alter TCR-based selection thresholds
remains an open and important question. It is clear that adju-
vants can directly or indirectly influence DC maturation (Ban-
Figure 7. Selection Threshold Is Reset Independently of the Antigen
Dose
(A) PCC-specific Th cells (Va11+Vb3+CD44hiCD62Llo) at day 7 in lymph nodes
from mice immunized with MPL-based adjuvant containing 400 mg (left), 40 mg
(middle), or 4 mg (right) of PCC.
(B) Total number of PCC-specific Th cells after immunization with 400, 40, 4,
and 0 mg PCC; mean ± SEM; nR 3; p < 0.05 (*) two-tail Student’s t test, com-
pared to any other antigen dose.
(C) Relative abundance of PCC-specific Th cells expressing Jb1.2 or Jb2.5
gene segments for indicated PCC dose; mean ± SEM; nR 3.
(D) Prevalence of five dominant TCRb chains expressing clonotypes compar-
ing 400 mg dose (data from Figure 3C) to 4 mg dose, mean ± SEM; n = 3.706 Immunity 28, 698–709, May 2008 ª2008 Elsevier Inc.chereau and Steinman, 1998; Medzhitov and Janeway, 1997).
Targeting various DC subsets either at the site of vaccination
or within draining lymphoid tissues can be influenced by the ad-
juvant formulation (Garcon et al., 2007; Guy, 2007; Kaufmann,
2007). The local antigen concentration is most readily influenced
by depot or nondepot formulations; however, the ‘‘downstream’’
consequences for DC maturation or Th cell priming in vivo re-
main poorly characterized. The capacity of a DC to uptake, pro-
cess, and present protein antigen can be altered by the inflam-
matory context of the priming event (Mellman and Steinman,
2001; Trombetta and Mellman, 2005). In this manner, vaccine
adjuvants can influence the level of pMHCII expressed bymature
DC. Further, the DC maturation program driven by different in-
nate signals can impact a multitude of cell surface and secreted
molecules that vary the cellular andmolecular context of pMHCII
expression (Pulendran and Ahmed, 2006). These changes in
antigen presentation can either positively or negatively impact
TCR-pMHCII interactions to regulate the clonal selection thresh-
old or its impact on antigen-specific Th cell fate.
Although Alum is the most widely used adjuvant for human
vaccines, its action in vivo remains poorly understood (Lindblad,
2004). Alum-precipitated protein provides an antigen depot as
well as a local irritant effect to the innate immune system. IFA
is also not metabolized in vivo and sets up local inflammation
with no known TLR-agonist activity (Billiau and Matthys, 2001;
Garcon et al., 2007). However, the mixture of TLR agonists in
heat-killed mycobacterium tuberculosis is complex, and the cel-
lular targets of adjuvant action must be varied but remain poorly
characterized (Billiau andMatthys, 2001; Garcon et al., 2007). Al-
though all three depot-forming formulations promoted lower
pMHCII-binding clonotypes, in TCR repertoire there were still
differences that may explain a differential impact on adaptive im-
munity (Pulendran and Ahmed, 2006). In contrast, the aqueous
CpG adjuvant is a simple dispersible TLR-9 agonist with soluble
antigen that independently reaches target cell populations (Klin-
man, 2006). Intracellular TLR-9 is expressed by DC subsets, and
CpG is known to drive DC maturation even in the absence of an-
tigen (Klinman, 2006). The MPL-based adjuvant can drive DC
maturation by TLR-4 agonist activity of the MPL itself and has
been added to Alum-based Hepatitis B vaccine formulations
for use in humans (Baldridge et al., 2004; Garcon et al., 2007).
This adjuvant formulation also contains squalene (Glenn and
O’Hagan, 2007) and Trehalose dimycolate (TDM) that may pro-
mote clonal expansion independently of TLR expression (Yama-
gami et al., 2001). Hence, it remains important to discriminate the
action of different adjuvants on the maturation of pMHCII-
expressing DC populations that in turn initiate clonal selection
in the antigen-specific Th cell compartment.
Understanding the mechanisms of immune protection after
vaccination is central to the rational design of all future vaccines.
Protein subunit vaccines are considered a safer alternative to at-
tenuated microorganisms and primarily depend on identifying
the appropriate antigen on the target pathogen. Effective protein
vaccination then relies heavily on the vaccine adjuvant formula-
tion to promote the development of long-term antigen-specific
immune protection (Guy, 2007; Kaufmann, 2007; Pashine
et al., 2005; Pulendran and Ahmed, 2006). Importantly, the
strength of pMHCII complex recognition by the TCR initiates
the progression of antigen-specific Th cell development (Gett
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Adjuvants Regulate TCR selectionet al., 2003; Iezzi et al., 1998; Lee et al., 2003; Miller et al., 2004)
with consequences for Th cell expansion and functional differen-
tiation (Celli et al., 2007; Chang et al., 2007; Lanzavecchia and
Sallusto, 2002; Reiner et al., 2007). Our current studies reveal
that adjuvants can regulate these initial TCR-based selection
events and alter the clonal composition of antigen-specific Th
cell compartment. We propose that this fundamental attribute
of adjuvants can be used to design effective new vaccine formu-
lations that also enhance long-term antigen-specific adaptive
immunity.
EXPERIMENTAL PROCEDURES
Mice
B10.BR, B10.BR-Thy1.1 congenic and 5C.C7ab, 5C.C7b, and 2B4b trans-
genic mice were maintained under pathogen-free conditions at The Scripps
Research Institute. The Scripps Research Institute and the Institutional Animal
Care and Use Committee reviewed and approved all experiments.
Protein Vaccination
Mice were immunized subcutaneously at the base of the tail with 400 mg, 40 mg
or 4 mg of whole PCC (Sigma) either precipitated in Alum (Jordan et al., 2004) or
in combination with CFA (Sigma), IFA (Sigma), 100 mg CpG ODN 1826 (Coley),
or monophosphoryl lipid A-based adjuvant (Ribi from Corixa and lab formula-
tion based on procedures in Baldridge and Crane [1999]). For the Alum and IFA
preparations, PCC was detoxified with the Detoxi-gel endotoxin removing gel
(Pierce).
Adoptive Transfer
For cotransfer experiments, splenocytes were transferred intravenously into
B10.BR-Thy1.1 congenic mice. The recipients were then immunized with
400 mg whole PCC in IFA or MPL-based adjuvant. For transfer experiments,
2 3 105 5C.C7ab splenocytes labeled or not with 5mM CFSE (carboxyfluores-
cein diacetate succinimidyl ester, Molecular Probes) for 10 min at 37C were
transferred intravenously into B10.BR mice or B10.BR-Thy1.1 congenic
mice at the time of immunization or 3 and 5 days after immunization with
PCC in IFA- or MPL-based adjuvant. Mice were sacrificed at various times
after transfer for analysis of cells by flow cytometry.
Flow Cytometry
As described (McHeyzer-Williams et al., 1999), single-cell suspensions from
lymphoid tissues in PBS with 5% FCS were labeled for 45 min at 4C at a den-
sity of 2.03 108 cells/ml with predetermined optimal concentrations of the fol-
lowing fluorophore-labeled monoclonal antibodies: fluorescein isothiocya-
nate-conjugated anti-Va11 (RR8.1), phycoerythrin (PE)-conjugated anti-Vb3
(KJ25), Allophycocyanin (APC)-conjugated anti-Vb3 (KJ25) and anti-CD44
(Pgp1; all produced in the lab), PE-conjugated anti-CD90.2 (30-H12), Cy5-
PE-conjugated anti-B220 (6B2) and anti-CD8a (53-6.7; all from BD Biosci-
ences), Cy5-PE-conjugated anti-CD8a (53-6.7) and anti-CD11b (M1/70),
Cy7-PE conjugated anti-CD62L (MEL14), Cy7-APC conjugated anti-CD4
(GK1.5; all from Biolegend), PE- and Cy7-PE-conjugated anti-CD4 (GK1.5),
APC-Alexa-Fluor-750-conjugated anti-CD44 (IM7), and Cy7-APC conjugated
anti-CD62L (MEL-14; all from eBioscience). PE-MCC/I-Ek tetramers (pMHCII
tetramer) prepared as previously described (Malherbe et al., 2004) were incu-
bated for 2 hr at room temperature at a final concentration of 230 nM. After
staining with tetramer, cells were washed twice and then labeled separately
on ice for 45 min with the labeled monoclonal antibodies to other cell-surface
antigens as described above. The cells we then suspended in 2 mg/ml propi-
dium iodide (PI) (for exclusion of dead cells) for analysis. Data were collected
on a FACS Vantage SE (BD Biosciences) and were analyzed with FlowJo
software (TreeStar). Profiles are presented as 5% probability contours with
outliers.
Single-Cell Repertoire Analysis
Single cells with the appropriate surface phenotype were sorted for repertoire
analysis with a FACS Vantage SE and CloneCyt software (BD Biosciences).The synthesis of cDNA and amplification of TCR Va11 and Vb3 regions were
carried out as previously described (McHeyzer-Williams et al., 1999). Direct
sequencing of the purified PCR products was carried out with a Va11-specific
or Vb3-specific primer with the BigDye Terminator cycle sequencing kit,
and sequences were analyzed on an ABI 373A DNA Sequencer (Applied
Biosystems).
Jb-Specific Single-Cell PCR
Two microliters of cDNA from single-cell cDNA reactions were first used for
amplification reactions of the TCRVb3, with primers specific for the Vb3 region
(Vb3.L2) and constant region (Cb.2) as previously described (McHeyzer-Wil-
liams et al., 1999). Onemicroliter of the first PCR product was used for Jb-spe-
cific amplifications with nested primer specific for Vb3 region (50-TATCTGGTG
AAAGGGCAAGG-30) and primer specific for Jb1.2 gene segment (50-
CCTGAGCCGAAGGTGTA GTC-30) or primer specific for Jb2.5 gene segment
(50-GCCCAAAGTACTGGGTGTCT-30). Second-round PCR reactions begins
with 95C for 5 min, continues with 35 cycles of 95C for 15 s, 55C for 45 s,
and 72C for 90 s, and ends with 72C for 5 min. We ran 5ml of second-round
PCR product on 1.5% agarose gel to screen for Jb1.2- and Jb2.5-expressing
cells.
Statistical Analysis
Data are shown as means ± standard error means (SEM) and were compared
with the one- or two-tailed Student’s t test with GraphPad Prism (GraphPad
Software).
SUPPLEMENTAL DATA
Six figures are available at http://www.immunity.com/cgi/content/full/28/5/
698/DC1/.
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